Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)

Wyeth

Status: Completed

Conditions: Vaccines, Pneumococcal Conjugate Vaccine

Treatments: Biological: Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)

Study type: Observational

Funder types: Industry

Identifiers

NCT00683410

0887X-102339

Details and patient eligibility

About

To collect post-marketing information on the safety of Prevenar in Filipino patients

Enrollment: 3,366 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• All patients from the study center who received or will receive at least one dose of Prevenar according to the approved product indication.

Exclusion criteria

• Previously discontinued Prevenar therapy due to safety concerns.

Trial design

3,366 participants in 1 patient group

1

Treatment:

Biological: Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)